Nuvalent Inc Cl A (NUVL) Stock Price, Quote & News

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) wh...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 357 7000

Website: www.nuvalent.com

Address:

One Broadway, 14th Floor, Cambridge, United States

ISEEITALLTHETIME Jul. 1 at 12:00 AM

$NUVL $NUVB $PFE $BMY $RHHBY Here's a question, why aren't they saying this about Nuvation's drug, it's already been approved? This is what I have been saying all along, Nuvalents drug is superior to Nuvation's drug.

2 · Reply

Shagg85 Jun. 30 at 8:49 PM

$BMY $NUVB $NUVL $PFE $RHHBY pump on your Own ticker. they aren’t even close to release or FDA approval

0 · Reply

Quantumup Jun. 30 at 8:39 PM

Goldman Sachs assigned $NUVL at a Buy-$105 after its previous No Rating on their Initiation, plus⬆️its peak sales ests for nela/zide to ~$7B WW non-risk-adj'd, or ~$5B risk-adj'd in 2040. $NUVB $PFE $BMY $RHHBY Goldman Sachs said in its note:

0 · Reply

IN0V8 Jun. 25 at 11:28 PM

$NUVL Buy Leerink Partners raises target price to $140 from $125 H.C. Wainwright raises target price to $130 from $110

0 · Reply

The_Fudster Jun. 25 at 7:03 PM

$NUVL interesting. Data yesterday was good but valuation was already quite rich. Little delayed reaction?

0 · Reply

Quantumup Jun. 24 at 5:18 PM

Leerink⬆️the PT on $NUVL to $140 from $125 and reiterated at an Outperform. $NUVB $PFE TPTX - $BMY $RHHBY Leerink said in its note to investors:

0 · Reply

JarvisFlow Jun. 24 at 3:04 PM

HC Wainwright & Co. has adjusted their stance on Nuvalent ( $NUVL ), setting the rating to Buy with a target price of 110 → 130.

0 · Reply

dgbio Jun. 24 at 11:34 AM

$NUVL $NUVB Zide shows much better DOR than Ibtrozi on TKI-pretreated patients. ORR is the same. Safety is much better as expected. DOR is a surprise. https://investors.nuvalent.com/2025-06-24-Nuvalent-Announces-Positive-Pivotal-Data-from-ARROS-1-Clinical-Trial-of-Zidesamtinib-for-TKI-Pre-treated-Patients-with-Advanced-ROS1-positive-NSCLC

1 · Reply

DylanGFM Jun. 24 at 3:45 AM

$NUVL ANOTHER DECENT LONG TERM INVESTMENT

0 · Reply

justiceforb_85 Jun. 23 at 8:58 PM

$NUVL look forward to the update on zidesamtinib tomorrow.

1 · Reply

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

Jun 23, 2025, 4:30 PM EDT - 14 days ago

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Jun 18, 2025, 4:30 PM EDT - 19 days ago

Nuvalent Appoints Christy Oliger to Board of Directors

May 8, 2025, 7:31 AM EDT - 2 months ago

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 1:09 PM EDT - 2 months ago

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Apr 23, 2025, 10:28 AM EDT - 2 months ago

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Apr 1, 2025, 6:30 AM EDT - 3 months ago

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Mar 25, 2025, 5:24 PM EDT - 3 months ago

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Feb 28, 2025, 6:30 AM EST - 4 months ago

Nuvalent to Participate in Upcoming March Investor Conferences

Feb 27, 2025, 6:30 AM EST - 4 months ago

Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 6:30 AM EST - 6 months ago

Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones

Jan 10, 2025, 1:22 PM EST - 6 months ago

Nuvalent: A Logical Acquisition Target

Dec 19, 2024, 6:30 AM EST - 7 months ago

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 6:30 AM EST - 7 months ago

Nuvalent Appoints Grant Bogle to Board of Directors

Nov 26, 2024, 6:52 AM EST - 7 months ago

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 6:30 AM EST - 8 months ago

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results

Sep 23, 2024, 12:34 PM EDT - 10 months ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 18, 2024, 4:05 PM EDT - 10 months ago

Nuvalent Announces Closing of Upsized Public Offering of Common Stock

Sep 17, 2024, 1:20 PM EDT - 10 months ago

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases

Sep 16, 2024, 10:23 PM EDT - 10 months ago

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock

Sep 16, 2024, 1:44 PM EDT - 10 months ago

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity

Sep 16, 2024, 11:18 AM EDT - 10 months ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 16, 2024, 7:00 AM EDT - 10 months ago

Nuvalent Announces Public Offering of Common Stock

Sep 14, 2024, 5:00 AM EDT - 10 months ago

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Sep 13, 2024, 9:53 AM EDT - 10 months ago

Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655

Sep 9, 2024, 6:30 AM EDT - 10 months ago

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

Aug 29, 2024, 6:30 AM EDT - 11 months ago

Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 6:30 AM EDT - 11 months ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results

Jul 22, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Jul 16, 2024, 6:30 AM EDT - 1 year ago

Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024

Jul 11, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 17, 2024, 12:19 PM EDT - 1 year ago

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Jun 14, 2024, 7:15 AM EDT - 1 year ago

Nuvalent: NVL-655 Could Bring Blockbuster Potential

May 29, 2024, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

May 16, 2024, 4:01 PM EDT - 1 year ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

May 9, 2024, 6:30 AM EDT - 1 year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Mar 5, 2024, 4:52 PM EST - 1 year ago

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

Feb 27, 2024, 6:30 AM EST - 1 year ago

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 27, 2024, 6:15 AM EST - 1 year ago

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

Feb 26, 2024, 2:55 PM EST - 1 year ago

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 12, 2024, 6:30 AM EST - 1 year ago

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Feb 1, 2024, 6:30 AM EST - 1 year ago

Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 6:30 AM EST - 1 year ago

Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones

Dec 21, 2023, 6:30 AM EST - 1 year ago

Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 14, 2023, 6:30 AM EST - 1 year ago

Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 6:30 AM EDT - 1 year ago

Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day

Oct 16, 2023, 9:55 PM EDT - 1 year ago

Nuvalent Announces Pricing of Public Offering of Common Stock

Oct 13, 2023, 6:30 AM EDT - 1 year ago

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

ISEEITALLTHETIME Jul. 1 at 12:00 AM

2 · Reply

Shagg85 Jun. 30 at 8:49 PM

$BMY $NUVB $NUVL $PFE $RHHBY pump on your Own ticker. they aren’t even close to release or FDA approval

0 · Reply

Quantumup Jun. 30 at 8:39 PM

0 · Reply

IN0V8 Jun. 25 at 11:28 PM

$NUVL Buy Leerink Partners raises target price to $140 from $125 H.C. Wainwright raises target price to $130 from $110

0 · Reply

The_Fudster Jun. 25 at 7:03 PM

$NUVL interesting. Data yesterday was good but valuation was already quite rich. Little delayed reaction?

0 · Reply

Quantumup Jun. 24 at 5:18 PM

Leerink⬆️the PT on $NUVL to $140 from $125 and reiterated at an Outperform. $NUVB $PFE TPTX - $BMY $RHHBY Leerink said in its note to investors:

0 · Reply

JarvisFlow Jun. 24 at 3:04 PM

HC Wainwright & Co. has adjusted their stance on Nuvalent ( $NUVL ), setting the rating to Buy with a target price of 110 → 130.

0 · Reply

dgbio Jun. 24 at 11:34 AM

1 · Reply

DylanGFM Jun. 24 at 3:45 AM

$NUVL ANOTHER DECENT LONG TERM INVESTMENT

0 · Reply

justiceforb_85 Jun. 23 at 8:58 PM

$NUVL look forward to the update on zidesamtinib tomorrow.

1 · Reply

dgbio Jun. 18 at 12:06 AM

$NUVB $NUVL

1 · Reply

Stmkr Jun. 13 at 6:04 AM

$NUVB Is $NUVL the reason for the sell the news reaction? NUVL is reporting topline data mid-2025 but only for TKI-experienced patients for now. Also whether the higher selectivity will preserve as high efficacy remains to be seen. NUVB has set the bar very high. And is approved now, not in a year.

0 · Reply

Samalex Jun. 11 at 6:19 AM

$NUVB $TNXP $NUVL $KALV Only 8 more trading days until the PDUFA decision date for Talectrectinib. It may come at any given moment between now and 6/23/25. Best of luck to all Nuvation Bio faithful 🙏

1 · Reply

Samalex Jun. 10 at 12:40 PM

$NUVB Nuvation is flying deep under the radar. Out of the approximately 10M StockTwit users, less than 2K users are watching Nuvation. If NUVB starts trending on the positive PDUFA decision for Talectrectinib, other users might rush in to jump onboard for a ride. With $NUVL trading at 5X book value and has a market valuation of $5.6B, $NUVB, with a mere $800M market cap and trading at 2X book value, has every reason to do the same as NUVL, in my amateur opinion. ************ Just my lay person’s take. Do your own diligence. ************

1 · Reply

BiotechBonesaw Jun. 8 at 3:13 PM

Because shorts are about to get crushed. Taletrectrinib may be the best-in-class ROS-1 inhibitor and has a likely approval in 15 days!! $NUVB . At this point: I will gladly take the alternate viewpoint and continue adding shares of Nuvation on any dip as I have been over the past few weeks. I think I’ll stop with the daily posts about Tonix’s likely approval for Tonmya (fibromyaglia) on a daily count given they’re 16 days away although that has more upside potential than either Nuvation or Nuvalent $NUVL Fellow $TNXP bulls - check out Nuvation (ROS1+ NSCLC) or Kalvista $KALV (a rare disease called HAE) for some likely June approvals. I’m not invested in Kalvista (yet!) but am excited for those patients to have an oral option. GLL! 👍 ☘️ 🚀 Patients are waiting. ⏰ ~Jeff 15 Days Away for Nuvation!

1 · Reply

BiotechBonesaw Jun. 8 at 2:42 PM

$NUVB $NUVL are two drastically different companies and this article only mentions them as developing ROS-1 assets. Keep in mind that Nuvalent’s lead asset is an ALK inhibitor and their ROS-1 is further away. If Nuvation drops further I’ll keep buying shares. Over 7K shares now ahead of the PDUFA GLL 👍 ☘️ 🚀 NUVL Pipeline (they won’t have an approval for another year - check back then as an investment)

0 · Reply

BiotechBonesaw Jun. 6 at 9:18 PM

$NUVB $NUVL I wish @Stocktwits had a polling feature so we could answer questions like this! 🧐 It would be interesting to track. 🤷‍♂️ Good luck to both companies, $PPBT , $KPTI , and all the undervalued biotechs fighting cancer ♋️

0 · Reply